ArticleMolecular and clinical oncology2025
Real‑world efficacy and safety data of immune checkpoint inhibitors in Turkish patients with metastatic melanoma: A Turkish oncology group retrospective study.
Article in Molecular and clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
37 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, significant success has been achieved in the treatment of metastatic melanoma with the use of immune checkpoint inhibitors (ICIs), and it resulted in a remarkable increase in patient survival. However, there are only a few studies reflecting daily practice outside of clinical trials. The present study aimed to evaluate the effectiveness and safety of ICI therapy in Turkish patients with metastatic melanoma, including those with poor prognostic factors such as advanced age and brain metastasis. A retrospective analysis was conducted on 249 patients diagnosed with metastatic melanoma and treated with ICIs at 23 cancer centers in Turkey. The efficacy and safety of treatment were investigated, and prognostic factors were examined. The mean age was 59 years, and 64% of patients were male. A total of 28% had BRAF mutation. A total of 22% of the patients were >70 years of age and 26% had brain metastases. The objective response rate with ICI therapy was 37.7%. The median overall survival (OS) was 61 months (95% CI 47-74.9), and the median progression-free survival was 7 months (95% CI 5.9-8). Examining factors influencing overall survival, the difference in median OS was not statistically significant by sex and BRAF status, whereas there were statistically significant differences by age, objective response status, metastasis pattern, and presence of brain metastasis. Median OS was 35 months in patients >70 years when compared with 67 months in patients aged 70 years and younger (P=0.02). Median OS was 41 months in patients without objective response, whereas it could not be reached in patients with objective response (P<0.0001). Median OS was 35 months in patients with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.